Furiex Pharmaceuticals (FURX)
Furiex Pharmaceuticals Market Cap: 190.04M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
FURX Market Cap Rankings
| Overall | 33rd percentile | 3114 of 4650 |
| Sector | 30th percentile | 613 of 882 in Services |
| Industry | 30th percentile | 67 of 97 in Business Services |
FURX Market Cap Range, Past 5 Years
| Minimum | 100.39M | Jun 2010 |
| Maximum | 235.12M | Mar 2012 |
| Average | 158.61M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these FURX related companies
FURX News
$FURX Insider Buy: $486K of stock bought by Fredric Eshelman on May 24, 2012 http://stks.co/3zhw
about 4 days ago by MarketBrief
about 4 days ago by MarketBrief
$FURX Insider Buy: $947K of stock bought by Fredric Eshelman between May 22, 2012 - May 23, 2012 http://stks.co/3ynz
about 5 days ago by MarketBrief
about 5 days ago by MarketBrief
Furiex Pharmaceuticals and Menarini Announce License Agreement for Priligy®
May 14, 5:33PM Business Wire
May 14, 5:33PM Business Wire
Furiex Pharmaceuticals Announces Agreement to Transfer Priligy® Product Rights
May 14, 5:30PM Business Wire
May 14, 5:30PM Business Wire
UPDATE: Ladenburg Thalmann Reiterates Buy Rating, Raises PT for Furiex Pharmaceuticals
May 14, 10:30AM Benzinga
May 14, 10:30AM Benzinga
@BioRunUp thats true about $furx vs $alxa but this response is a little bit better than theirs.
about 25 days ago by BioTechZeek
about 25 days ago by BioTechZeek
RT @peterumble $RGEN $POZN $FURX who wants to hold for the weekend? #FLUSHTHATTURD $$ (haha i'm done with spec biotech. short articles daily
about 32 days ago by johnkelly
about 32 days ago by johnkelly
$RGEN $POZN $FURX who wants to hold for the weekend? #FLUSHTHATTURD $$
about 32 days ago by peterumble
about 32 days ago by peterumble
RT @peterumble $FURX $RGEN No Buyers, all SELLERS? $$ (don't 4get $POZN)
about 32 days ago by johnkelly
about 32 days ago by johnkelly
$FURX $RGEN selloff on FDA CRL/withdrawal bad news, markets $SPY weaker #SHORTS $$
about 32 days ago by peterumble
about 32 days ago by peterumble
$FURX is -5.0% down since open on unusual high volume and -5.2% down since close.
about 32 days ago by TradeBot
about 32 days ago by TradeBot
@epime7heus for $FURX. But not sure where it goes from here short term. Consensus seems to be back down. Then a wait for next PDUFA try.
about 32 days ago by epime7heus
about 32 days ago by epime7heus
http://stks.co/3XIO Health Care Report Take A Look $FURX $BMY $AMLN
about 33 days ago by Stockmarketman2
about 33 days ago by Stockmarketman2
@voda then let's cash in. $$ $FURX ..in the Interim that mark I stated is the current resistance. Almost there
about 33 days ago by ACE52WeekHigh
about 33 days ago by ACE52WeekHigh
@ACE52WeekHigh $furx i think it's got more room than 16.25. It was sold on an over reaction
about 33 days ago by voda
about 33 days ago by voda
Furiex Pharmaceuticals Announces First Quarter 2012 Earnings Release and Conference Call
Apr 03, 4:05PM Business Wire
Apr 03, 4:05PM Business Wire
Ladenburg Thalmann Starts Furiex Pharmaceuticals (FURX) at Buy, Sets $30 Price Target
Mar 02, 10:13AM Street Insider
Mar 02, 10:13AM Street Insider
Furiex Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Earnings Release and Conference Call
Jan 23, 4:05PM Business Wire
Jan 23, 4:05PM Business Wire
Furiex (FURX) Says PPD-10558 Did Not Meet Primary Efficacy Endpoint in Phase II Trial
Dec 08, 5:01PM Street Insider
Dec 08, 5:01PM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| FURX | 19.10 | +0.88 | +4.83% | 190.04M |
| FUR | 10.30 | -0.10 | -0.96% | 340.42M |
| FUND | 6.26 | +0.06 | +0.97% | |
| FUN | 26.60 | +0.13 | +0.49% | 1.473B |
| FULT | 10.24 | -0.04 | -0.39% | 2.051B |
| FSYS | 15.10 | -0.24 | -1.56% | 302.15M |
| FSTR | 27.66 | -0.04 | -0.14% | 283.52M |
| FST | 8.43 | +0.22 | +2.68% | 988.08M |
| FSS | 4.88 | +0.04 | +0.83% | 303.44M |
| FSRV | 26.32 | +0.17 | +0.65% | 753.28M |